34 results about "Activation lymphocyte" patented technology

The invention provides a kit for detecting human regulatory T cell subtypes and a detection method and belongs to the technical field of cell subtype detection. The provided kit comprises components as follows: a blood diluent, a mononuclear cell separation medium, a cell culture fluid, a lymphocyte activation solution, dead cell removal dyes, an FcR blocking agent, a fluorescence labeled antibodyresisting human cell surface labeling molecules, a fluorescence labeled antibody resisting human intracellular molecules, a PBS buffer solution, lipopolysaccharide, a washing buffer solution, a celldyeing buffer solution, a cell fixing solution and a permeable membrane lotion. During detection, firstly, mononuclear cells in whole blood are separated, then, mononuclear cells of human peripheral blood are stimulated, finally, a fluorescent antibody is stained, and the regulatory T cell subtypes can be detected. By use of the kit and the detection method, 2-6 regulatory T cell subtypes can be simply and rapidly distinguished.

The invention relates to peptides having an amino acid sequence substantially homologous to an amino sequence of a domain of a pyrogenic exotoxin, which domain forms a central turn in the exotoxin starting within β-strand 7 and connecting the β-strand 7, via short β-strand 8, to α-helix 4, and ending within α-helix 4, based on the domain numbering of Staphylococus aureus enterotoxin B. The peptides of the invention are capable of antagonizing toxin-mediated activation of T-lymphocytes, do not have agonist activity, and are capable of eliciting protective immunity against toxic shock induced by a pyrogenic exotoxin or by a mixture of pyrogenic exotoxins. The invention also relates to broad spectrum pharmaceutical compositions for the treatment, protection against or short term prophylaxis of toxin-mediated activation of T cells, comprising as active ingredient at least one peptide according to the invention or a derivative thereof, and to broad spectrum vaccines for conferring long term immunity against toxic shock induced by at least one pyrogenic exotoxin.

The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.

The invention discloses combination measuring, and discloses a method used for measuring the MHC II combination activity of Lymphocyte activationgene-3(LAG-3) protein, or fragments, derivatives, or analogues of Lymphocyte activationgene-3(LAG-3) protein. The method comprises measuring of the LAG-3 protein, the fragments, the derivatives, or the analogues using biolayer interferometry (BLI). The method can be used for quality control measuring of the compounds in good manufacturing practice (GMP) grade production. The invention also discloses a probe and a kit of the method.

The invention belongs to the technical field of gene science and technology, and particularly relates to a method for researching activation and differentiation of B lymphocytes by an interferon-induced gene IFIT3, which comprises the following steps: step 1, collecting peripheral blood of clinically diagnosed SLE patients and healthy control persons, extracting peripheral blood mononuclear cells (PBMC) by Ficoll, and separating and purifying B cells by adopting immunomagnetic beads; step 2, culturing an in-vitro induced hair growth center B cell (iGCB), and detecting the change condition of an IFIT3 transcript by a fluorescent quantitative PCR (qRTPCR) technology; 3, overexpressing IFIT3 through an iGCB system, inducing and differentiating into plasma cells (iPC), and detecting main regulatory factors IRF4, Pax5 and Bcl6 for differentiating the B cells into the plasma cells through flow analysis; and 4, exploring epigenetic modification of the IFIT3 protein by using technologies such as mass spectrum, co-immunolocalization, Western-blot, molecular cloning and the like, and discussing the influence of the interferon-induced gene IFIT3 on activation and differentiation functions of B lymphocytes, thereby providing a scientific basis for clarifying the pathogenesis of lupus and finding targets for treating lupus in the future.

The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.